Table 3.
Parameter estimates for the pharmacokinetic/pharmacodynamic model
| CYP2C9*1/*1 | CYP2C9*1/*13 | |
|---|---|---|
| Parameter | Estimate (%RSE) | Estimate (%RSE) |
| CL (L/h) | 0.320 (1.35) | 0.147 (2.12) |
| Vc (L) | 5.24 (6.35) | 3.38 (22.9) |
| Q (L/h) | 3.41 (18.5) | 3.38 (22.4) |
| Vp (L) | 5.18 (6.89) | 4.55 (20.4) |
| ka (/h) | 5.01 (9.18) | 5.27 (8.48) |
| DT (h) | 2.99 (0.140) | 2.96 (0.242) |
| F | 0.653 (2.25) | 0.713 (8.79) |
| kout (/h) | 0.912 (17.2) | |
| γ | 0.739 (9.62) | |
| IC50 (ng/mL) | 1390 (10.2) | |
| tlag = DT, kin = 100*kout | ||
CL, apparent clearance; DT, duration for meloxicam to enter the central compartment from the absorption compartment by zero‐order rate; F, fraction of the dose absorbed by zero‐order absorption; IC50, plasma meloxicam concentrations that decrease kin by 50%; ka, first‐order absorption rate constant; kout, first‐order rate constant for the decrease in percent serum thromboxane B2 relative to the basal value; Q, apparent intercompartmental clearance; Vc, apparent volume of distribution in the central compartment; Vp, apparent volume of distribution in the peripheral compartment; γ, sigmoidicity parameter.